Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : View from the Center and Left -- Ignore unavailable to you. Want to Upgrade?

To: TimF who wrote (14818)	3/22/2006 11:20:47 AM
From: JohnM	Read Replies (1) \| Respond to of 543046

I just don't see any way to get a net benefit from public financing. This post harks well back in the queue. But then I've been traveling. A bit more about that in a subsequent post. As for public funding of campaign financing, I'm definitely not arguing that it's problem free. Rather that it's much better than the present one in which large donors simply buy their favored representative, senator and off they go. This is already reasonably transparent but I expect it to get even more so as we get further into the Abramoff/Wade public disclosures and trials. And, I expect, disclosures that have little to do with those two. Your objection to the notion of private financing for initial efforts to become a serious and funded candidate is that it permits corruption to leak into the system. That's hardly a deal breaker since the amount of money required to become a publicly funded candidate would be well short of present requirements to fund a full campaign. Even at the level of the House of Representatives, those numbers, in contested districts are very large. Not to speak of the amount of money representatives in uncontested races raise for their PACs so they can, in turn, increase their legislative clout by offering money to their colleagues in contested ones. The clearest illustration, to me, at least recently, of the corrupting power of money is that portion of the prescription drug medicare bill in which the government is not permitted to price bargain. No system is going to be perfect; any proposed system can be critiqued as imperfect. The best standard is just how much of an improvement over the present system it represents.